AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

NEXT STORY
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease
PREV STORY
Alignment Health Plan to Launch New PPO, C-SNP and D-SNP Options to Meet Growing, Diverse Needs of 5 Million Seniors in California
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Mateon Provides Update on OT-101

author_avatar
NASDAQ Market News

RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H. pylori Infection

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update

author_avatar
NASDAQ Market News